CVAC
CureVac N.V.
Company Overview
| Mkt Cap | $1.17B | Price | $5.03 |
| Volume | 1.38M | Change | -1.76% |
| P/E Ratio | 7.2 | Open | $5.11 |
| Revenue | $535.2M | Prev Close | $5.12 |
| Net Income | $162.2M | 52W Range | $2.48 - $5.72 |
| Div Yield | N/A | Target | $4.30 |
| Overall | 45 | Value | -- |
| Quality | -- | Technical | 45 |
No chart data available
About CureVac N.V.
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Latest News
CureVac’s New mRNA Study: A Potential Game-Changer in Lung Cancer Treatment
CureVac Announces Extraordinary Meeting for Merger with BioNTech
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CVAC | $5.03 | -1.8% | 1.38M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |